Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 5;33(3):1197-1212.
doi: 10.1016/j.ymthe.2025.01.010. Epub 2025 Jan 10.

Characterization of a novel conditional knockout mouse model to assess efficacy of mRNA therapy in the context of severe OTC deficiency

Jenny Zhou  1 , Shi Liang  1 , Ling Yin  1 , Andrea Frassetto  1 , Anne-Renee Graham  1 , Rebecca White  1 , Maria Principe  1 , Madelyn Severson  1 , Tiffany Palmer  1 , Shan Naidu  1 , Eric Jacquinet  1 , Mike Zimmer  1 , Patrick F Finn  2 , Paolo G V Martini  3
Affiliations

Characterization of a novel conditional knockout mouse model to assess efficacy of mRNA therapy in the context of severe OTC deficiency

Jenny Zhou et al. Mol Ther. .

Abstract

Ornithine transcarbamylase deficiency (OTCD) is the most common urea-cycle disorder, characterized by hyperammonemia and accompanied by a high unmet patient need. mRNA therapies have been shown to be efficacious in hypomorphic Sparse-fur abnormal skin and hair (Spf-ash) mice, a model of late-onset disease. However, studying the efficacy of ornithine transcarbamylase (OTC) mRNA therapy in traditional knockout mice, a model for severe early-onset OTCD, is hampered by the rapid lethality of the model and poor lipid nanoparticle (LNP) uptake into neonatal mouse liver. We developed a novel tamoxifen-inducible mouse to study the effect of mRNA therapy in the context of complete or near-complete OTC loss in adult animals. Characterization of the model showed that it is highly reproducible, 100% penetrant, and phenocopies hallmarks of human disease, with animals exhibiting decreased body weight, hyperammonemia, and brain edema. Delivery of OTC mRNA increased survival, maintained body weight, delayed the onset of hyperammonemia, and reduced brain edema. Therefore, this model provides a platform to study LNP-mediated mRNA therapies for the treatment of late-onset OTCD.

Keywords: LNP-mediated delivery; OTC; OTCD; conditional knockout; mRNA therapy; mouse model; ornithine transcarbamylase deficiency.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests J.Z., S.L., L.Y., A.F., A.-R.G., M.P., M.S., S.N., M.Z., and P.F.F. are employees and shareholders of Moderna, Inc. R.W., T.P., E.J., and P.G.V.M. are former employees of Moderna, Inc.

References

    1. Tuchman M., Lee B., Lichter-Konecki U., Summar M.L., Yudkoff M., Cederbaum S.D., Kerr D.S., Diaz G.A., Seashore M.R., Lee H.-S., et al. Cross-sectional multicenter study of patients with urea cycle disorders in the United States. Mol. Genet. Metab. 2008;94:397–402. doi: 10.1016/j.ymgme.2008.05.004. - DOI - PMC - PubMed
    1. Wraith J.E. Ornithine carbamoyltransferase deficiency. Arch. Dis. Child. 2001;84:84–88. doi: 10.1136/adc.84.1.84. - DOI - PMC - PubMed
    1. Caldovic L., Abdikarim I., Narain S., Tuchman M., Morizono H. Genotype–Phenotype Correlations in Ornithine Transcarbamylase Deficiency: A Mutation Update. J. Genet. Genomics. 2015;42:181–194. doi: 10.1016/j.jgg.2015.04.003. - DOI - PMC - PubMed
    1. Choi J.-H., Lee B.H., Kim J.H., Kim G.-H., Kim Y.-M., Cho J., Cheon C.-K., Ko J.M., Lee J.H., Yoo H.-W. Clinical outcomes and the mutation spectrum of the OTC gene in patients with ornithine transcarbamylase deficiency. J. Hum. Genet. 2015;60:501–507. doi: 10.1038/jhg.2015.54. - DOI - PubMed
    1. Summar M.L., Koelker S., Freedenberg D., Le Mons C., Haberle J., Lee H.-S., Kirmse B., European Registry and Network for Intoxication Type Metabolic Diseases. Members of the Urea Cycle Disorders Consortium The incidence of urea cycle disorders. Mol. Genet. Metab. 2013;110:179–180. doi: 10.1016/j.ymgme.2013.07.008. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources